Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is try to evaluate the effect of cetuximab monotherapy as maintenance treatment,
versus continuation after 8 courses of induction therapy with cetuximab plus standard
chemotherapy regimen (FOLFIRI or mFOLFOX6）in metastatic colorectal cancer (mCRC) patients.
The maintenance treatments are continued until disease progression or untolerated toxicity.
The aim of this study is to demonstrate that cetuximab monotherapy is non-inferior to
continuation treatment, in those mCRC patients who responded to induction therapy(SD, PR, or
CR), and carry biomarker-panels (KRAS, NRAS, BRAF, and PIK3CA) favor EGFR antibody.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ruijin Hospital
Collaborators:
Chinese PLA General Hospital Tongji Hospital West China Hospital Xiangya Hospital of Central South University